UY31044A1 - Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno - Google Patents
Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogenoInfo
- Publication number
- UY31044A1 UY31044A1 UY31044A UY31044A UY31044A1 UY 31044 A1 UY31044 A1 UY 31044A1 UY 31044 A UY31044 A UY 31044A UY 31044 A UY31044 A UY 31044A UY 31044 A1 UY31044 A1 UY 31044A1
- Authority
- UY
- Uruguay
- Prior art keywords
- combination
- cancer
- progesterone
- antiestrogen
- brca
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title abstract 4
- 229940046836 anti-estrogen Drugs 0.000 title abstract 2
- 230000001833 anti-estrogenic effect Effects 0.000 title abstract 2
- 239000000328 estrogen antagonist Substances 0.000 title abstract 2
- 229960003387 progesterone Drugs 0.000 title abstract 2
- 239000000186 progesterone Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 102000036365 BRCA1 Human genes 0.000 abstract 2
- 108700020463 BRCA1 Proteins 0.000 abstract 2
- 101150072950 BRCA1 gene Proteins 0.000 abstract 2
- 102000052609 BRCA2 Human genes 0.000 abstract 2
- 108700020462 BRCA2 Proteins 0.000 abstract 2
- 101150008921 Brca2 gene Proteins 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- -1 4-acetylphenyl Chemical group 0.000 abstract 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 201000004458 Myoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 229940123788 Progesterone receptor antagonist Drugs 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 206010027191 meningioma Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Uso individual del antagonista del receptor de progesterona 11B.(4-acetilfenil) -17B-hidroxi-17a-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona, o un derivado o un análogo de éste como fármaco, para la profilaxis y el tratamiento del cáncer de mama mediado por BRCA1 o BRCA2, y combinacion que comprende el antagonista del receptor de progesterona mencionado, o un derivado o un análogo de éste para uso farmacéutico, con al menos un antiestrogeno puro, para la profilaxis y el tratamiento del cáncer de mama mediado por BRCA1 o BRCA2, el cáncer de ovario, el cáncer de endometrio, el cáncer gástrico, el cáncer colorrectal, la endometriosis,el mieloma, el mioma y el meningioma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07090083 | 2007-04-23 | ||
| US91437207P | 2007-04-27 | 2007-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31044A1 true UY31044A1 (es) | 2008-11-28 |
Family
ID=39671992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY31044A UY31044A1 (es) | 2007-04-23 | 2008-04-22 | Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090029954A1 (es) |
| EP (1) | EP2136796A2 (es) |
| JP (1) | JP2010524997A (es) |
| AR (1) | AR066234A1 (es) |
| CA (1) | CA2683809A1 (es) |
| CL (1) | CL2008001148A1 (es) |
| PA (1) | PA8777301A1 (es) |
| PE (1) | PE20090152A1 (es) |
| TW (1) | TW200904451A (es) |
| UY (1) | UY31044A1 (es) |
| WO (1) | WO2008128791A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130231292A1 (en) * | 2012-03-02 | 2013-09-05 | Wei Zhou | Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells |
| KR20180059427A (ko) * | 2015-07-14 | 2018-06-04 | 노벨파마 컴퍼니 리미티드 | 에스트로겐 수용체 α 저해 작용을 갖는 에스트로겐 수용체 β 부분 아고니스트 및 이를 사용한 부인과 질환 치료제 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| IL154975A0 (en) * | 2000-10-18 | 2003-10-31 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| EP1326617B9 (en) * | 2000-10-18 | 2006-10-25 | Schering Aktiengesellschaft | Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
-
2008
- 2008-04-21 EP EP08773335A patent/EP2136796A2/en not_active Withdrawn
- 2008-04-21 WO PCT/EP2008/003333 patent/WO2008128791A2/en not_active Ceased
- 2008-04-21 US US12/106,554 patent/US20090029954A1/en not_active Abandoned
- 2008-04-21 JP JP2010504551A patent/JP2010524997A/ja active Pending
- 2008-04-21 CA CA002683809A patent/CA2683809A1/en not_active Abandoned
- 2008-04-22 PE PE2008000687A patent/PE20090152A1/es not_active Application Discontinuation
- 2008-04-22 UY UY31044A patent/UY31044A1/es not_active Application Discontinuation
- 2008-04-22 AR ARP080101670A patent/AR066234A1/es unknown
- 2008-04-22 CL CL2008001148A patent/CL2008001148A1/es unknown
- 2008-04-22 PA PA20088777301A patent/PA8777301A1/es unknown
- 2008-04-22 TW TW097114661A patent/TW200904451A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008128791A3 (en) | 2008-12-11 |
| PE20090152A1 (es) | 2009-04-30 |
| EP2136796A2 (en) | 2009-12-30 |
| CL2008001148A1 (es) | 2008-11-03 |
| TW200904451A (en) | 2009-02-01 |
| US20090029954A1 (en) | 2009-01-29 |
| PA8777301A1 (es) | 2008-11-19 |
| CA2683809A1 (en) | 2008-10-30 |
| WO2008128791A2 (en) | 2008-10-30 |
| JP2010524997A (ja) | 2010-07-22 |
| AR066234A1 (es) | 2009-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002098A1 (es) | “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct | |
| CL2007003266A1 (es) | Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas. | |
| MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
| CL2019001567A1 (es) | Anticuerpo conjugado que se une a la región constante del receptor de células t beta 1 (trbc1) o trbc2. (divisional solicitud 201803096) | |
| HN2012000137A (es) | Derivados de 17 - hidroxi - 17 - pentafluoroetil - estra - 4, 9(10) - dien - 11 - arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades | |
| CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
| MX2015016171A (es) | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. | |
| ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
| GEP20197011B (en) | Heteroaryl compounds for kinase inhibition | |
| IL192816A (en) | Permanent pattern erasers, pharmaceutical preparations containing them and their use in the preparation of drugs | |
| MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
| MX2009006284A (es) | Arilpirazoles sustituidos. | |
| ECSP11011054A (es) | Péptidos antivirales terapéuticos | |
| PH12021550048A1 (en) | Selective estrogen receptor degraders. | |
| MX2023007810A (es) | Compuestos de complejo de hierro para uso terapeutico. | |
| CL2008003266A1 (es) | Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales. | |
| DK2018169T3 (da) | Anvendelse af 4,17-beta-dihydroxyandrost-4-en-3-on til behandling af cancer | |
| AR070456A1 (es) | Combinacion que comprende paclitaxel para el tratamiento de cancer de ovario y su uso | |
| UY31044A1 (es) | Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno | |
| CY1121190T1 (el) | Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης | |
| MX2010006047A (es) | Mezcla ceramica a prueba de fuego, cuerpo moldeado ceramico a prueba de fuego, formado con la mezcla y su uso. | |
| CL2017002890A1 (es) | Paneles de yeso | |
| PA8777501A1 (es) | Combinación de antagonista del receptor de progesterona con antiestrógenos no esteroidales para usar en enfermedades mediadas por brca | |
| MX2021003500A (es) | Uso de un inhibidor de un transportador de la familia ent en el tratamiento del cáncer y su combinación con un antagonista del receptor de adenosina. | |
| PE20090734A1 (es) | Combinacion de antagonista del receptor de progesterona con antiestrogenos no esteroidales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20171005 |